Innovative Health Sciences has announced its commercialisation team expansion for marketing the Insignis Syringe Infusion System.
The move follows the US Food and Drug Administration (FDA) clearance of the system in March 2024.
Featuring a 13.5psi mechanical syringe driver and a selectable rate flow control device, the system is designed for both intravenous (IV) and subcutaneous use, offering a convenient infusion solution for various patient settings.
Innovative Health Sciences has named Justyn Okoniewski as sales vice president. He will be responsible for accelerating commercialisation and business growth.
The Insignis Syringe Infusion System combines IV and subcutaneous infusion capabilities in a non-electric pump with a highly accurate selectable rate flow control device.
This system aims to enhance patient autonomy, allowing them to adjust the flow rate as needed, potentially reducing common site reactions associated with infusions.
The Insignis Intravenous Controller features a selectable flow rate dial for direct IV catheter connection to administer medication.
The OneSett Subcutaneous Administration Set includes a flow controller for up to four 26-gauge needle configurations, simplifying the infusion process for 20% subcutaneous immunoglobulin (SCIg) solutions.
Innovative Health Sciences also provides a range of needle sets and the Q-Controller Subcutaneous Administration Set, specifically designed for 10% IgG medications like Hyqvia, capable of delivering up to 300ml/h to each site.
The Insignis System has also received CE Mark approval, and certification under MDSAP and ISO 13485 standards.
Innovative Health Sciences founder and chairman Andrew Sealfon said: “With the FDA clearance for our unique approach to delivering medications, including the novel tapered flow technique, we're on the cusp of shifting the paradigm in our field, making critical infusions more comfortable, affordable, and accessible than ever.
“I'm excited to welcome Justyn to the team where he will help lead IHS into the next phase of development and growth.”
